Patient P-01878
Synthetic patientNBL-101 · Day 117 · 45–54 · F · baseline S05Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
16%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S05
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Treatment adherence+9
- Toxicity-3
- GI instability+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion27.4/100
improving · -6.3 vs previous 14 d
Toxicity
Blood11.8/100
worsening · +0.7 vs previous 14 d
Sleep quality
Wearable24.5/100
worsening · -1.6 vs previous 14 d
Energy level
Daily log5.3/10
improving · +0.3 vs previous 14 d
Stress level
Daily log4/10
stable · -0.2 vs previous 14 d
Steps
Wearable8,767
improving · +667 vs previous 14 d
Adherence
Companion98 %
stable · +3.4 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 81 from the failing basin, 15 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
Main detractors to watch
- Spicy / capsaicinperturbation · steering -8.8
- Bacteroides fragilis elevatedhidden · steering -7.4
- IL6 high-expression varianthidden · steering -7.3
- Antibiotic courseperturbation · steering -4.7
- Spicy / capsaicindetractor · GI +5.1 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Spicy / capsaicin+5.1detractor · 95%
- Histamine load-1.2no signal · 24%
- Dietary fat load-0.6no signal · 15%
- Simple carbohydrates+0.3no signal · 15%
- Insoluble fibre+0.1no signal · 15%
- Alcohol+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑45
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Autonomic recovery ↑20
- WearableShort sleep window
- Mucosal barrier integrity ↓10
- WearableSleep 5.1 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 4.5 · butyrate capacity 74/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 40 ms
- Sleep
- 6.1 h
- Steps
- 9,138
- Resting HR
- 69 bpm
Daily log: GI score 27, nutritional resilience 61, adherence 98.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01766 | 43% | S05 | AD-05 | no change | 90 |
| P-01804 | 29% | S19 | AD-05 | improved | 61 |
| P-01541 | 24% | S09 | AD-05 | no change | 43 |
| P-01329 | 48% | S08 | BR-03 | improved | 79 |
| P-01495 | 42% | S07 | BR-03 | improved | 85 |
| P-01677 | 40% | S05 | BR-03 | no change | 86 |
| P-01689 | 24% | S13 | BR-03 | no change | 50 |
| P-01654 | 45% | S08 | CR-01 | improved | 85 |
| P-01430 | 25% | S05 | CR-01 | improved | 54 |
| P-01479 | 36% | S15 | DT-01 | improved | 84 |
| P-01855 | 33% | S04 | DT-01 | improved | 73 |
| P-01767 | 30% | S14 | DT-01 | no change | 63 |